ArticleChemistryOpen2026
In Silico, In Vitro, and In Vivo Antinociceptive Potential of S-Naproxen Derivatives.
Article in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Selected naproxen derivatives were investigated for their antinociceptive effects, using in vitro (COX-I/COX-II antagonistic effect), in vivo (acetic acid and hot plate assay), and in silico (molecular simulation studies) approaches. The COX inhibition studies revealed that the maximum percent effect exhibited by GMO-I-111a 96.01 and 92% against COX-2 and COX-1, respectively, at higher concentrations. The effect at minimum concentration was 81 and 77% against COX-1 and COX-2, respectively. The COX antagonist effect of GMO-I-9a and GMO-I-11a was also outstanding in the acetic acid assay. All the tested derivatives demonstrated a significant (p < 0.05) analgesic effect at all concentrations (1.25, 2.5, and 10 mg/kg). The maximum effect was found against GMO-I-135a (95%), followed by GMO-I-11a (92%). The central analgesic effect of various derivatives was significant (p < 00.1). GMO-I-111a exhibited a significant (p < 00.1) analgesic effect after 30 min at all the tested doses. The maximum effect at higher doses was shown by compound GMO-I-9a (93%) followed by GMO-I-11a (88%), GMO-I-111a (84%), and GMO-I-135a (78%). The latency time of GMO-I-9a and GMO-I-135a was significantly reversed by naloxone treatment, indicating the central analgesic effect. The molecular simulation studies showed that all the tested compounds had good binding interactions with COX-1/COX-2, except GMO-I-9a. In conclusion, the tested naproxen derivatives might have a significant analgesic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.